---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-009253"
form_type: "8-K"
ticker: "PASG"
cik: "0001787297"
company_name: "Passage BIO, Inc."
filed_at: "2023-05-11T23:59:59+00:00"
generated_at: "2026-06-15T04:31:08.289630+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Passage Bio reports Q1 2023 net loss of $34.3M; cash runway into H1 2025

## Summary
- Cash, cash equivalents and marketable securities $167.8M as of March 31, 2023, down from $267.1M a year ago; expected to fund operations into first half 2025.
- Net loss $34.3M ($0.63 per share) for Q1 2023, compared to $42.8M ($0.79 per share) in Q1 2022.
- R&D expenses $16.8M, down from $26.2M YoY; G&A expenses $19.0M, up from $15.1M due to non-recurring Catalent amendment costs.
- On track to report interim clinical data for PBGM01 (GM1 gangliosidosis) and PBFT02 (FTD) in 2023; protocol amendment submitted for higher dose of PBGM01.
- Initiated fourth global trial site for upliFT-D trial; expect to dose first patient at Dose 3 in second half 2023.

## SEC filing metadata
- accession: 0001558370-23-009253
- form_type: 8-K
- ticker: PASG
- cik: 0001787297
- company_name: Passage BIO, Inc.
- filed_at: 2023-05-11T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/0001558370-23-009253-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/pasg-20230511x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-009253
- JSON: https://secwatch.observer/filing/0001558370-23-009253.json
- Plain text: https://secwatch.observer/filing/0001558370-23-009253.txt

## Key facts
- Earnings Releases
  Passage BIO, Inc. reported the quarter ended March 31, 2023 results: net income $34.3 million, EPS $0.63 per basic and diluted share.
  - Period: the quarter ended March 31, 2023
  - Net income: $34.3 million
  - EPS: $0.63 per basic and diluted share
  - Result: reported results
  source text: Net loss was $34.3 million, or a net loss of $0.63 per basic and diluted share, for the quarter ended March 31, 2023, compared to $42.8 million, or a net loss of $0.79 per basic and diluted share, for the same quarter in 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1787297/000155837023009253/0001558370-23-009253-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.